Nymox Pharmaceutical Corp (NYMX)

5.07
0.62 14.00
NASDAQ : Health Care
Prev Close 4.45
Open 5.30
Day Low/High 4.70 / 5.79
52 Wk Low/High 1.62 / 4.58
Volume 10.43M
Avg Volume 541.00K
Exchange NASDAQ
Shares Outstanding 46.15M
Market Cap 112.13M
EPS -0.50
P/E Ratio 5.79
Div & Yield N.A. (N.A)

Latest News

Nymox Pharmaceuticals (NYMX) Stock Surges on Prostate Drug Progress

Nymox Pharmaceuticals (NYMX) Stock Surges on Prostate Drug Progress

Nymox Pharmaceuticals (NYMX) is working to get its fexapotide drug approved and may partner with a larger company to help market the medication.

Nymox Announces Prostate Drug Progress

Nymox Announces Prostate Drug Progress

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Nymox Pharmaceutical Corporation

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Nymox Pharmaceutical Corporation

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Nymox Pharmaceutical Corporation (NASDAQ: NYMX) resulting from allegations that Nymox...

Nymox Reports Long-Term Prostate Cancer Results In 7 Year Prospective Study Of 995 U.S. Middle-Aged And Elderly Men Without Cancer

Nymox Reports Long-Term Prostate Cancer Results In 7 Year Prospective Study Of 995 U.S. Middle-Aged And Elderly Men Without Cancer

Study Shows Major Reduction to Cumulative Incidence of Prostate Cancer in Study to 1.3%

5 Stocks Insiders Love Right Now

5 Stocks Insiders Love Right Now

Insiders at these companies have been scooping up shares of their own companies lately.

4 Biotech Stocks Under $10 to Trade for Breakouts

4 Biotech Stocks Under $10 to Trade for Breakouts

These under-$10 biotech stocks are within range of triggering breakout trades.

Nymox Pharmaceutical (NYMX) Stock Higher on Positive Test Results

Nymox Pharmaceutical (NYMX) Stock Higher on Positive Test Results

Nymox Pharmaceutical (NYMX) shares continue to climb on promising BPH treatment candidate results.

Nymox Announces $850,000 Financing

Nymox Announces $850,000 Financing

Nymox Pharmaceuticals (NYMX) Stock Drops Today Following Monday's Climb

Nymox Pharmaceuticals (NYMX) Stock Drops Today Following Monday's Climb

Shares of Nymox Pharmaceuticals (NYMX) were down in late morning trading Tuesday as investors took some profits following the stock's surge on Monday.

Nymox Pharmaceuticals (NYMX) Stock Spikes Today on Prostate Cancer Trial Data

Nymox Pharmaceuticals (NYMX) Stock Spikes Today on Prostate Cancer Trial Data

Shares of Nymox Pharmaceuticals (NYMX) surged Monday after the company announced long-term clinical trial results from its NX-1207 Phase 2 prostate cancer study NX03-0040.

Nymox Announces New Prostate Cancer Clinical Trial Results

Nymox Announces New Prostate Cancer Clinical Trial Results

Significantly Better Clinical Outcomes After Up to 2.8 Years for NX-1207 Prostate Cancer Treated Patients Compared to Control Group

Nymox Pharmaceuticals (NYMX) Stock Declines Today After Week of Significant Gains

Nymox Pharmaceuticals (NYMX) Stock Declines Today After Week of Significant Gains

Shares of Nymox Pharmaceuticals (NYMX) were down Monday as investors took profits following four straight days of gains last week in which the stock rose more than 175%.